159164-17-7

Upstream product

• 954106-16-2 C₂₁H₂₉NO₃ 
• 954106-37-7 (4R,5S)-3-(3,7-dimethyloct-6-enoyl)-4-methyl-5-phenyl-2-oxazolidinone 
• 954106-23-1 C₃₇H₄₅NO₆ 
• 77943-39-6 4-methyl-5-phenyloxazolidin-2-one 

Downstream Products

• 131472-58-7 (4R,5S)-3-{2-[4-(4-Methoxy-benzyloxy)-phenyl]-acetyl}-4-methyl-5-phenyl-oxazolidin-2-one 
• 121441-79-0 <4R,5S>-3-<1-oxo-2-(methoxy)ethyl>-4-methyl-5-phenyl-2-oxazolidinone 
• 954106-39-9 C₂₅H₃₁NO₄ 
• 94418-35-6 (4R,5S)-3-((4'R,5'R,6'S)-bicyclo<4.3.0>nonene-4'-carbonyl)-4-methyl-5-phenyl-2-oxazolidinone 
• 94418-35-6 (4R,5S)-3-((3aS,4S,7aR)-2,3,3a,4,5,7a-Hexahydro-1H-indene-4-carbonyl)-4-methyl-5-phenyl-oxazolidin-2-one 
• 220907-93-7 3-[2-(4-methoxy-phenyl)-2-(4-nitro-imidazol-1-yl)-propionyl]-4-methyl-5-phenyl-oxazolidin-2-one 
• 220536-12-9 C₂₂H₂₀N₄O₅ 
• 220536-14-1 C₂₂H₂₀N₄O₅ 
• 131472-59-8 (4R,5S)-3-{(R)-2-[4-(4-Methoxy-benzyloxy)-phenyl]-pent-4-enoyl}-4-methyl-5-phenyl-oxazolidin-2-one 
• 175356-50-0 (4R,5S)-3-{(E)-(2R,3S,6S)-6-[(2R,3S,5S,6R)-6-(tert-Butyl-dimethyl-silanyloxy)-3-methoxy-5-methyl-tetrahydro-pyran-2-yl]-3-hydroxy-2-methoxy-4-methyl-hept-4-enoyl}-4-methyl-5-phenyl-oxazolidin-2-one 
• 185342-17-0 (4R,5S)-3-[2-(3-Chloro-4-methoxy-phenyl)-acetyl]-4-methyl-5-phenyl-oxazolidin-2-one 
• 166533-65-9 (+)-N-<1-oxo-5-(tert-butyldimethylsilyl)oxy-6-methylhept-6-ene>-2-methyl-3-phenyl-4-oxazolidin-5-one 
• 184867-88-7 (+)-N-(1-oxo-6-methylhept-6-ene)-2-methyl-3-phenyl-4-oxazolidin-5-one 
• 94418-28-7 (4R,5S)-3-((E,E)-2',7',9'-decatrienoyl)-4-methyl-5-phenyl-2-oxazolidinone 

Relevant academic research and scientific papers

Studies toward the synthesis of pinnatoxins: the spiroimine fragment

An enantioselective approach to the spiroimine fragment of pinnatoxins is described. The strategy is based on a recently developed diastereoselective Ireland-Claisen rearrangement to establish the challenging congested quaternary and tertiary stereocenters within the cyclohexene ring.

Method for treating emesis with ghrelin agonists

The present invention relates to a method comprising administering to a patient diagnosed as being in need of treatment for nausea, emesis, or symptoms associated therewith comprising administering to a patient in need thereof a compound of formula (I) wh